In prostate cancer, DUSP1 efficiently dephosphorylated JNK 11; in hepatocellular carcinoma, DUSP1 mainly inhibits the p38/MAPK pathway 12; and in this study, DUSP1 deficiency promoted EC progression via the ERK/MAPK pathway. Here, MAPK8 is linked to prostate cancer.